AR049096A1 - Formulacion en aerosol sin gas propelente para la inhalacion de beta-agonistas - Google Patents
Formulacion en aerosol sin gas propelente para la inhalacion de beta-agonistasInfo
- Publication number
- AR049096A1 AR049096A1 ARP050101959A ARP050101959A AR049096A1 AR 049096 A1 AR049096 A1 AR 049096A1 AR P050101959 A ARP050101959 A AR P050101959A AR P050101959 A ARP050101959 A AR P050101959A AR 049096 A1 AR049096 A1 AR 049096A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- halogen
- hydrogen
- enantiomers
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000000443 aerosol Substances 0.000 title 1
- 229940125388 beta agonist Drugs 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 150000002431 hydrogen Chemical class 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 2
- 150000001450 anions Chemical class 0.000 abstract 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 abstract 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 abstract 1
- 229910002651 NO3 Inorganic materials 0.000 abstract 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 abstract 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000013583 drug formulation Substances 0.000 abstract 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 abstract 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 abstract 1
- 229960001860 salicylate Drugs 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 abstract 1
- 229940095064 tartrate Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Reivindicacion 1: Formulacion medicamentosa que contiene como unico principio activo uno o varios compuestos de la formula general (1), en la que significan: R1 es hidrogeno, alquilo C1-4, alcoxi C1-4 o halogeno; R2 es hidrogeno, alquilo C1-4, alcoxi C1-4 o halogeno; R3 es hidrogeno, alquilo C1-4, alcoxi C1-4 o halogeno, OH, -O-alquilenC1-4-COOH u -O-alquilen-C1-4-COO-alquiloC1-4; X- anion de carga negativa simple, con preferencia un anion de carga negativa simple seleccionado del grupo compuesto por cloruro, bromuro, yoduro, sulfato, fosfato, metansulfonato, nitrato, maleato, acetato, benzoato, citrato, salicilato, trifluoroacetato, fumarato, tartrato, oxalato, succinato, benzoato y ptoluensulfonato; eventualmente en forma de sus tautomeros, enantiomeros, mezclas de enantiomeros, racematos o solvatos, al menos un ácido farmacologicamente tolerable, eventualmente otros coadyuvantes y/o formadores de complejos farmacologicamente tolerables, y como disolvente agua, etanol o una mezcla de agua y etanol.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004024452A DE102004024452A1 (de) | 2004-05-14 | 2004-05-14 | Aerosolformulierung für die Inhalation von Betaagonisten |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR049096A1 true AR049096A1 (es) | 2006-06-28 |
Family
ID=34979667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050101959A AR049096A1 (es) | 2004-05-14 | 2005-05-13 | Formulacion en aerosol sin gas propelente para la inhalacion de beta-agonistas |
Country Status (26)
| Country | Link |
|---|---|
| EP (1) | EP1809293B1 (es) |
| JP (1) | JP4620730B2 (es) |
| KR (1) | KR101288791B1 (es) |
| CN (1) | CN101056640A (es) |
| AR (1) | AR049096A1 (es) |
| AU (1) | AU2005244414B2 (es) |
| BR (1) | BRPI0511135B8 (es) |
| CA (1) | CA2564379C (es) |
| DE (1) | DE102004024452A1 (es) |
| DK (1) | DK1809293T3 (es) |
| EA (1) | EA012583B1 (es) |
| EC (1) | ECSP067004A (es) |
| ES (1) | ES2575925T3 (es) |
| HU (1) | HUE027780T2 (es) |
| IL (1) | IL179218A (es) |
| MX (1) | MXPA06013216A (es) |
| MY (1) | MY148403A (es) |
| NO (1) | NO20065030L (es) |
| PE (1) | PE20060311A1 (es) |
| PL (1) | PL1809293T3 (es) |
| SG (1) | SG152265A1 (es) |
| TW (1) | TWI356703B (es) |
| UA (1) | UA87312C2 (es) |
| UY (1) | UY28891A1 (es) |
| WO (1) | WO2005110421A2 (es) |
| ZA (1) | ZA200607462B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7056916B2 (en) | 2002-11-15 | 2006-06-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
| US7220742B2 (en) | 2004-05-14 | 2007-05-22 | Boehringer Ingelheim International Gmbh | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
| MX2008001976A (es) | 2005-08-15 | 2008-03-25 | Boehringer Ingelheim Int | Procedimiento para la preparacion de betamimeticos. |
| EA200801139A1 (ru) * | 2005-11-09 | 2008-10-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Композиция для аэрозольной ингаляции |
| UY30543A1 (es) * | 2006-08-18 | 2008-03-31 | Boehringer Ingelheim Int | Formulacion de aerosol para la inhalacion de beta- agonistas |
| WO2010057927A1 (en) * | 2008-11-21 | 2010-05-27 | Boehringer Ingelheim International Gmbh | Aerosol formulation for the inhalation of beta agonists |
| EP2358350A1 (en) * | 2008-11-21 | 2011-08-24 | Boehringer Ingelheim International GmbH | Aerosol formulation for the inhalation of beta agonists |
| JP2015533131A (ja) | 2012-10-09 | 2015-11-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 咳を治療するためのベータ２−アドレナリン受容体作動薬 |
| WO2018108669A1 (en) | 2016-12-12 | 2018-06-21 | Boehringer Ingelheim International Gmbh | Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with olodaterol |
| BR112022010802A2 (pt) * | 2019-12-05 | 2022-08-23 | Syngenta Crop Protection Ag | Processo de um passo para a preparação de derivados de feniletilamina |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3134590A1 (de) * | 1981-09-01 | 1983-03-10 | Boehringer Ingelheim KG, 6507 Ingelheim | Neue benzo-heterocyclen |
| US4460581A (en) * | 1982-10-12 | 1984-07-17 | Boehringer Ingelheim Kg | (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones |
| JPH0637388B2 (ja) * | 1986-02-17 | 1994-05-18 | 千寿製薬株式会社 | 水性液剤 |
| GB9405019D0 (en) * | 1994-03-15 | 1994-04-27 | Smithkline Beecham Plc | Novel compounds |
| DE10253282A1 (de) * | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung |
| EP1781298B1 (de) * | 2004-04-22 | 2012-01-04 | Boehringer Ingelheim International GmbH | Arzneinmittelkombinationen enthaltend benzoxazine zur behandlung von atemwegserkrankungen |
| DE102004019539A1 (de) * | 2004-04-22 | 2005-11-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittel zur Behandlung von Atemwegserkrankungen |
| DE102004024454A1 (de) * | 2004-05-14 | 2005-12-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| DE102004024451A1 (de) * | 2004-05-14 | 2005-12-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten |
-
2004
- 2004-05-14 DE DE102004024452A patent/DE102004024452A1/de not_active Withdrawn
-
2005
- 2005-05-10 JP JP2007512068A patent/JP4620730B2/ja not_active Expired - Lifetime
- 2005-05-10 CN CNA2005800154865A patent/CN101056640A/zh active Pending
- 2005-05-10 KR KR1020067026225A patent/KR101288791B1/ko not_active Expired - Lifetime
- 2005-05-10 DK DK05747843.0T patent/DK1809293T3/en active
- 2005-05-10 MX MXPA06013216A patent/MXPA06013216A/es active IP Right Grant
- 2005-05-10 BR BRPI0511135A patent/BRPI0511135B8/pt active IP Right Grant
- 2005-05-10 EP EP05747843.0A patent/EP1809293B1/de not_active Expired - Lifetime
- 2005-05-10 CA CA2564379A patent/CA2564379C/en not_active Expired - Lifetime
- 2005-05-10 ES ES05747843.0T patent/ES2575925T3/es not_active Expired - Lifetime
- 2005-05-10 UA UAA200612949A patent/UA87312C2/ru unknown
- 2005-05-10 WO PCT/EP2005/005028 patent/WO2005110421A2/de not_active Ceased
- 2005-05-10 HU HUE05747843A patent/HUE027780T2/en unknown
- 2005-05-10 PL PL05747843.0T patent/PL1809293T3/pl unknown
- 2005-05-10 SG SG200902777-2A patent/SG152265A1/en unknown
- 2005-05-10 EA EA200602017A patent/EA012583B1/ru not_active IP Right Cessation
- 2005-05-10 AU AU2005244414A patent/AU2005244414B2/en not_active Expired
- 2005-05-11 UY UY28891A patent/UY28891A1/es not_active Application Discontinuation
- 2005-05-12 PE PE2005000529A patent/PE20060311A1/es not_active Application Discontinuation
- 2005-05-12 MY MYPI20052158A patent/MY148403A/en unknown
- 2005-05-13 TW TW094115491A patent/TWI356703B/zh not_active IP Right Cessation
- 2005-05-13 AR ARP050101959A patent/AR049096A1/es unknown
-
2006
- 2006-09-06 ZA ZA200607462A patent/ZA200607462B/en unknown
- 2006-11-02 NO NO20065030A patent/NO20065030L/no not_active Application Discontinuation
- 2006-11-13 IL IL179218A patent/IL179218A/en active IP Right Grant
- 2006-11-13 EC EC2006007004A patent/ECSP067004A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR062424A1 (es) | Formulacion en aerosol para la inhalacion de beta - agonistas | |
| CO6170341A2 (es) | Formulacion de aerosol que contiene derivados de benzoxazin-3onas | |
| AR058082A1 (es) | Formulacion en aerosol para la inhalacion de beta- agonistas | |
| WO2005030211A8 (de) | Aerosolformulierung für die inhalation enthaltend ein anticholinergikum | |
| AR049096A1 (es) | Formulacion en aerosol sin gas propelente para la inhalacion de beta-agonistas | |
| MY150519A (en) | Imidazoquinolines with immuno-modulating properties | |
| JP5064213B2 (ja) | Ｂｃｌタンパク質と結合パートナーとの相互作用を阻害する化合物および方法 | |
| AR124662A2 (es) | Formulaciones inmunosupresoras | |
| JP2013529196A5 (es) | ||
| MY130803A (en) | New quinuclidine amide derivatives | |
| WO2008115098A3 (fr) | 2,3,4,5-tétrahydro-1h-pyrido[4,3-b]indoles substitués ainsi que procédés de leur fabrication et leur utilisation | |
| CN105431432B (zh) | 奎宁类化合物、其光学异构体及其制备方法和医药用途 | |
| AR065772A1 (es) | Compuestos de indolobenzazepina para el tratamiento de la hepatitis c. composiciones farmaceuticas. | |
| AR037248A1 (es) | Compuestos de n-benzoil-5-tiofen-2-sulfonamida y n-benzoil-2-tiazol-5-sulfonamida, formulacion farmaceutica que los comprende y su uso para fabricacion de un medicamento | |
| NZ590987A (en) | Quinuclidine carbonate derivatives and medicinal composition thereof | |
| JP2010501022A5 (es) | ||
| AR057180A1 (es) | Formulacion farmaceutica de absorcion oral que comprende insulina, entre otros, y su metodo de administracion | |
| AR039404A1 (es) | Combinaciones de medicamentos que contienen compuestos heterociclicos y un agente anticolinergico. aerosol para su inhalacion | |
| AR098745A2 (es) | Composición, kit y uso de compuestos quimioterapéuticos | |
| CN111467351A (zh) | 用于治疗疾病的方法 | |
| AR039275A1 (es) | Medicamento que contiene esteroides y un nuevo anticolinergico | |
| TW200630364A (en) | 2-amido-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof | |
| AR039935A1 (es) | Formulacion farmaceutica de liberacion inmediata | |
| TW200616636A (en) | Novel compounds | |
| AR049650A1 (es) | Derivados 5-aril-1h-pirrol[2,3-b]piridin-3-carboxamida o acido 5-aril-1h-pirrol[2,3-b]piridin-3-carboxilico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |